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1. INTRODUCTION
1.1 The C-type natriuretic peptide as an endogenous regulator
C-type natriuretic peptide (CNP), an endogenous substance, plays an important role in 
the control of circulation through the regulation of vascular tone. This endogenous peptide 
belongs to the natriuretic peptide (NP) family besides atrial natriuretic peptide (ANP) [1], 
brain natriuretic peptide (BNP) [2], urodilatin [3] and dendroaspis natriuretic peptide 
(DNP);[4]. Natriuretic peptides and their receptors have been identified in a wide range of 
vertebrate species from elasmobranchs to mammals [5]. NPs act more specifically on Na+ 
regulation in lower species, in mammals their key role is to maintain the physiologic body 
fluid homeosthasis and blood pressure. [6]. CNP was firstly identified in 1990 by Sudoh et al.
[2] from porcine brain extract as a peptide having 22 amino acid residues and showing 
sequence homology to ANP and BNP within the ring structure formed by an intramolecular 
disulfid linkage. Facing this structural relation CNP is distinct from ANP and BNP both 
genetically and functionally. Unlike ANP and BNP it acts as a paracrine, local modulator and 
not as a systemic hormone. Furthermore, facing it’s name C-type natriuretic peptide, it has no 
significant effect on renal fluid or electrolyte excretion [7].
Besides its presence in the central nervous system [8] and kidney [9], the CNP is an 
important regulator of cartilage homeostasis and endochondral bone growth [10]. It is 
produced by the vascular endothelium in a constitutive manner [11,12]. Although CNP was 
discovered as a neuromodulator, soon the vascular effects of the peptide came into 
prominence: 1/ it is an effective smooth muscle relaxant [13,14] and 2/ a potent anti­
proliferative and anti-migratory substance on vascular smooth muscle cells [15,16].
1.2. Effector systems of CNP
CNP exerts its biological effects by binding to cell surface receptors denoted NP 
receptor B and C (NPR-B, NPR-C, respectively).
The activation of the particulate guanylyl cyclase linked NPR-B receptor increases the 
intracellular cGMP level that provokes the relaxation of smooth muscle cells [17,18].
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Figure 1.
The role of C-type natriuretic peptide in cGMP-linked vasodilation.
The figure is pointing at the receptorial effect of C-type natriuretic peptide. The peptide binds 
to the NPR-B receptor that results in activation of guanylyl cyclase. The elevated production 
of cGMP leads to vasodilation through protein kinase G activation and through cGMP-gated 
ion channels by the reduction of intracellular Ca2+ concentration. NO exerts vasorelaxation 
through the same mechanism albeit the source of cGMP is the soluble guanylyl cyclase.
In contrast to NPR-B, NPR-C does not contain guanylyl cyclase domain and has no 
direct effect on cGMP levels [19].
The mechanism of CNP induced vasorelaxation through cGMP-gated ion channels is 
not exactly clear at present. However, it is supposed to exert a regulatory effect on Ca2+ - 
activated K+ channels (Kca -s) of the smooth muscle cell membrane and results in its 
hyperpolarization [20;21;22;23].
1.3. K+ channels; their subtypes
The activation of potassium channels is the main determinant of the cell membrane 
potential. Therefore, potassium channels participate in the regulation of vascular tone. 
Endothelium-dependent vasodilators, i.e. nitric oxide (NO), prostacyclin, and endothelium- 
derived hyperpolarizing factor (EDHF), may activate K+ channels in the cell membrane which 
allows K+ efflux out of the cell. The ionic efflux decreases the membrane potential and the 
consequent hyperpolarization closes voltage-gated calcium channels in the cell membrane and 
exerts vascular muscle relaxation.
With respect to kinetic properties, regulation, pharmacology and structure, potassium 
channels constitute the most diverse class of ion channels. Endothelial cells and vascular 
smooth muscle cells express four different classes of potassium ion channels: 1) voltage-gated 
potassium channels (Kv); 2) Ca2+ -activated potassium channels (KCa), including large - (BK), 
intermediate - (IK), and small-conductance (SK) Ca2+-activated potassium channels; 3) ATP- 
sensitive potassium channels (KAtp); and 4) inwardly rectifying potassium channels (Kir) [24].
The vast family of potassium channels is subdivided into three subfamilies: the 2 
transmembrane (2TM), the 4TM and 6TM channels [25,26]. Each subfamily of potassium 
channels generally consists of a primary pore forming a subunit, that is associated with 
several regulatory subunits [27].
Channels of 2 TM and 4TM family were not the subject of our study.
The 6TM family includes the voltage-gated potassium (Kv) channels, the KCNQ 
channels, the EAG channels (also including HERG channels), and the calcium -activated 
potassium channels BK (Slo) and SK.
On the basis of a subunit differences Kv channels are divided to the following groups: 
Kv 1.x (Shaker), Kv 2.x (Shab), Kv 3.x (Shaw) and Kv 4.x (Shal); the presence of Shaker and 
Shab type channels has been identified in smooth muscle and mesenteric arteries. These 
channels are sensitive to the blocker 4-aminopyridin (4-AP).
KCNQ channels (KCNQ1-5), also known as Kv 7.1 -7.5 have significant role in the 
repolarization of cardial action potential, but they are also found in kidney, brain and lungs.
Further, possibly 4-aminopyridin sensitive voltage dependent channels are the EAG 
(KylO.x, KV11.X, Kyi2.x) channels that have crucial role in cardiac repolarization.
Structurally, the calcium-activated potassium channels can be divided into two groups: 
the small or intermediate conductance potassium channels (SK/IK), and the high conductance 
potassium channels (BK, or Maxi-K). The open probability of these channels is increased by 
the elevation of intracellular calcium, leading to membrane hyperpolarization. BK channels 
consisting of a pore forming a and a regulatory p subunit affect the regulatory mechanisms of 
contraction in smooth muscle cells [24,26,27]. The channels - SK and IK -  responsible for 
hyperpolarization have also been found in smooth muscle.
Table 1. Calcium activated potassium channel subtypes of 6TM family
a Subunit Name Alternative Names Distribution Function
BK KCNMA1, Slo, Maxi- 
K+,K ca 1.1
Brain, skeletal 
muscle, smooth 
muscle, adrenal 
cortex, kidney
Smooth muscle: 
regulation of 
contraction (Heppner, 
1997)
Neurons:
hyperpolarization of 
plasma membrane
SK SKI-3 (KCa 2.1-2.3) 
SK4(IKcal,Kca3.1)
Brain, aorta, lung, 
skeletal muscle, 
smooth muscle, 
erythrocytes
Involved in the 
afterhyperpolarization 
in vertebrate neurons; 
volume regulation in 
erythrocytes
1.4. Elimination of CNP
CNP is eliminated through the above mentioned NPR-C receptors, but another very 
significant way of elimination, the enzymatic metabolism is also present. The main enzymatic 
elimination pathway of CNP is neutral endopeptidase (EC. 3.4.24.11, NEP). The NEP is a 
membrane bound zinc-containing metallopeptidase that cleaves various vasoactive peptides 
exerting various effects on the blood vessel tone [28]. Some of these peptides have 
vasodilating activity such as ANP, bradykinin or substance P, while others are 
vasoconstrictors i.e. endothelin [29-32].
CNP
inactive fragments
NPR-C
internalization
Figure 2.
Elimination pathways of CNP
Neutral endopeptidase EC.3.4.24.11. (NEP) enzyme degrades C-type natriuretic peptide to 
inactive fragments representing its main elimination pathway. The NPR-C receptor mediates 
the cellular internalization and subsequent lysosomal degradation of the peptide.
2. AIMS
The main aim of the present work was to study the vasorelaxing capacity of CNP on 
conductance type of isolated rat systemic and porcine coronary arteries as well as on the 
resistance type of human penile arteries. The involvement of the vascular endothelium in the 
mechanism of vasorelaxation and an elimination pathway of the peptide were investigated by 
using pharmacological inhibitors. The effect of CNP as well as that of two potent vasodilators 
on the hyperpolarization of the smooth muscle membrane as a possible cause of 
vasorelaxation were studied in porcine coronary artery. Kv and BKca channels, as mediators 
of hyperpolarization were studied in porcine coronary and human penile arteries, respectively. 
Our studies were focused on the following:
1/ Determination of the efficacy of CNP on rat isolated carotid, mesenteric and 
femoral arteries.
2/ The possible involvement of the vascular endothelium in the vasorelaxing 
mechanism of CNP in porcine isolated coronary artery. The effect of the endothelin inhibitor, 
PD142893.
3/ The role of NEP-enzyme, as an important elimination pathway of CNP in porcine 
isolated coronary artery. The effect of the inhibitors of NEP-enzyme, phosphoramidon and 
thiorphan, on CNP-induced relaxation.
4/ Hyperpolarizing effect of CNP and its comparison to the calcium sensitezer 
levosimendan and to a new vasodilator, OR2828, in porcine isolated coronary artery.
5/ Correlation between hyperpolarization and vasorelaxation induced by OR2828 in 
porcine isolated coronary artery. The involvement of 4-aminopyridine-sensitive Kv channels 
in the mechanism of action of OR2828.
6/ Endothelium independent vasorelaxation and hyperpolarization of CNP in 
resistance type penile arteries isolated from humans. Comparison to the endothelium- 
dependent relaxant, acetylcholine.
7/ Involvement of BKca channels in the non-nitrergic/non prostaglandin type of CNP- 
induced vasorelaxation in human resistance type of penile arteries.
3. MATERIALS AND METHODS
3.1. Effect of C-type NP on isolated femoral, mesenteric and carotid arteries of the rat
3.1.1. Tissue preparation and measurement of isometric tension
The peripherial blood vessels of the rat were investigated on three different types of 
isolated arteries, such as a. femoralis, a. mesenterica superior and a. carotis externa. Rats were 
anesthetized by aether, and following exsanguination, arterial samples were obtained for the 
studies. 2 mm long ring segments were cleaned from the surrounding tissues and 
longitudinally two stainless-steel wires were inserted to their lumen. The wires were fixed to 
the headstage of a Mulvany-type myograph for isometric measurement of tension. The water- 
jacketed baths contained 2 ml KH solution. The KH solution had the following composition 
(in mM): NaCl 120, KC1 4.2, CaC^ 1.5, NaHCC>3 20, MgCh 1.2, KH2PO4 1.2, and glucose 
11, pH=7.4. The rings were stretched up to an optimalized force according to Mulvany et al. 
[33] in order to achieve maximum active contractions. Two ring segments were investigated 
simultaneously. In every 15 min, during 45 min stabilization period, the arterial preparations 
were washed with fresh KH solution and then the initial passive tone was readjusted.
3.1.2. Experimental protocol
Active contractions were induced by KC1 (80 mM). After the stabilization of 
contractile tone CNP was administered cumulatively (1 nM -  1 pM) or was given in one 
single dose (1 pM).
3.2. Effect of CNP on the vascular tone and membrane potential in isolated porcine 
coronary arteries
3.2.1. Tissue preparation and measurement of isometric tension
Fresh porcine hearts, obtained from the local slaughterhouse, were placed in a 
container filled with ice-cold KH solution and transported to the laboratory within half an 
hour. Upon receipt of the heart, epicardial coronary arteries of the circumflex branch were 
carefully dissected. The vessels were cleaned of fat and the surrounding connective tissue, and 
cut into cylindrical rings of 5 mm length with a pair of blades set to fixed distance.
Two coronary rings of each porcine heart were mounted separately in isolated tissue baths 
containing 2 ml of KH solution bubbled with 95% O2 and 5% CO2 at 37 °C. The rings were 
suspended between a force-displacement transducer (Hugo-Sachs Elektronic, Type F30, 
Germany) and an anchor, and output data were recorded on a polygraph (KUTESZ, Hungary). 
The preparations were streched up to 30 mN and allowed to equilibrate for 90 min. Within 
this equilibration period the incubation medium was changed in every 15 min and responses 
to 30 mM potassium chloride (KC1) were produced in order to stabilize the contractile activity 
of the coronary artery rings.
3.2.2. Tissue preparation for membrane potential measurements
The source and preparation of porcine epicardial coronary arteries were the same as 
described before in 2.1.1. Coronary artery rings were cut open along the longitudinal axis and 
pinned to the bottom of an organ chamber (0.5 ml in volume) with the intimal surface upward.
3.2.3. Measurement of the membrane potential
The isolated vascular segments were superfused at a constant flow (2 ml min'1) with 
KH solution (37C°, aerated with 95% 0 2/5% C 02 gas mixture, pH 7.4). The transmembrane 
potential of the smooth muscle cells was measured using a conventional glass microelectrode 
technique. Glass electrodes were produced by Flaming/Brown micropipette puller (Model-97, 
Shutter Instruments Co. USA) from standard borosilicate glass capillaries (single-barrel, 
D=1.2 mm; World Precision Instruments Inc., Sarasota, FL, USA). The resistance of the tip 
filled with KC1 solution (3M) was 30 to 90 MG. The microelectrode was advanced using a 
pipette holder containing Ag/AgCl pellet in contact with the bathing solution and was directly
connected to the headstage of a recording amplifier (Intra 767, World Precision Instruments 
Inc., Sarasota, FL, USA) with capacitance neutralization. The Ag/AgCl reference electrode 
was placed directly in the organ chamber. The holder was mounted on a three-dimensional 
mechanical micromanipulator (Wetzlar, Leitz, Germany) placed on a vibration-free table. The 
signal was continuously monitored and recorded both on 80807-00 Cole Palmer Solid State 
Paperless Data Recorder at 4 Hz and Radelkis OH 814/1 type Potentiometric Recorder.
The microelectrode was inserted into a single muscle cell from the endothelial side. The 
following criteria were used to assess the validity of a successful impalement: (1) a sudden 
negative drop in potential from the baseline (zero potential reference) followed by (2) a stable 
negative voltage for more than 3 min; and (3) an instantaneous return to the previous voltage 
level on dislodgement of the microelectrode. Hyperpolarizing effect of 5 pM pinacidil proved 
the position of the electrodes within the smooth muscle cell and not in the endothelial cells.
3.2.4. Experimental protocol for the measurement of isometric tension
In order to observe the role of endothelium, experiments were performed on 
endothelium intact and endothelium deprived ring segments. In the case of endothelium 
deprived arterial rings the endothelium was mechanically removed from the intimal surface of 
the blood vessel by rubbing the intimal surface with a stainless steel rod covered with a cotton 
swab.
In experiments designed to determine the presence or absence of functional 
endothelium, after equilibration of the pairs of ring segments, contractions to the 
prostaglandin analogue, 0.75 pM U46619 were induced. When the steady-state contraction 
amplitude produced by U46619 had developed, both the endothelium-intact and the 
endothelium-deprived rings were exposed to bradykinin (1 pM) or A23187 (0.5 pM).
In another series of experiments the capacity of the combined NEP/ECE enzyme inhibitor, 
phosphoramidon, to influence relaxations caused by CNP was assessed. In each experiment 
two parallel coronary artery rings were mounted in separate organ baths: both were either 
endothelium intact or endothelium deprived preparations. During the equilibration period, 30 
min prior to the addition of the contractile agent, 0.75 pM U46619, phosphoramidon (10 pM) 
to one bath and its solvent (20 pi of 96% ethanol) to the other were added. Then at the steady-
state contraction amplitude of U46619 CNP was applied in a cumulative manner (0.006-1.4 
pM) to both coronary artery preparations.
In a third series of experiments the ability of the specific NEP-enzyme inhibitor, 
thiorphan to influence the coronary relaxations by CNP was investigated. Thiorphan was 
administered to one of the coronary rings in a concentration of 10 pM, while the other one 
was preincubated with its solvent (20 pi of 96% ethanol). Experiments were conducted with 
either two endothelium intact or two endothelium denuded coronary rings. Contractions to 
U46619 and concentration-response curves for CNP were established as described above with
phosphoramidon.
The effect of endothelin receptor inhibition was also studied on CNP-induced 
coronary artery relaxation by using the non-specific endothelin receptor antagonist, 
PD 142893. The agent (10 pM) and its solvent (20 pi of 96% ethanol) were added to the organ 
bath 30 min prior to U46619 and then a single concentration of CNP (0.02 pM) was applied 
to the coronary rings with and without endothelium. The experiments were perfomed with 
paired arterial rings as described above.
The vasorelaxant effect of OR-2828 (0.38 pM -  230.6 pM) was assumed on KC1 
(80mM) precontracted porcine isolated coronary arteries as described before in case of CNP. 
In a separate group of experiments the effect of the solvent used for the drug was investigated. 
The possible capacity of the Kv channel inhibitor, 4-aminoyridine (4-AP), to influence the 
relaxation evoked by OR-2828 has also been investigated. In each experiment two 
endothelium intact rings were mounted parallel in seperate organ baths. One of the rings was 
pretreated with 4-aminopyridine (5 mM), while the other one was preincubated with the 
corresponding volume of the 4-aminopyridine solvent (20 pi distilled water). After 10 
minutes both rings were precontracted with 30 mM KC1, and then OR-2828 (41.6-230.6 pM) 
was administered in a cumulative manner. Because the solvent of OR-2828 exerted 
significant relaxing effect at and above the volumes corresponding to 117.2 and 230.6 pM 
OR-2828 (90 and 180 pi solvent, respectively), the mean effects of the solvents were 
subtracted from the effects of the vasodilator.
3.2.5. Experimental protocol for the measurement of membrane potential
Arterial strips were equilibrated for 45 min at 37±0.1 °C before the microelectrode 
was inserted. Solutions of the tested substances were given directly into the organ chamber in 
single doses. CNP was dissolved in distilled water, and the following concentrations were 
applied: 0.7 pM, 1.4 pM, 2.4 pM. OR-2828 was added in concentrations of 60 pM, 120 pM 
and 180 pM; its solvent had the following composition: NaHC03 50 mM, NaOH 100 mM, 
glucose 25 mM and ethanol in 1/18 ratio. Levosimendan was administered in 3.7 pM 
concentration in a solution containing 692 mM Na2P04 and 6 mM NaOH.
3.3. Investigation of the effect of CNP on isolated human penile arteries
3.3.1. Preparation of human penile arteries
Penile erectile tissue was obtained in connection with transsexual operations. All 
patients had been cross dressing, living as women (mean age 29, range 18—49, n-14). Before 
surgery, each underwent a complete psychiatric and medical evaluation. The penis was 
excised and submerged immediately in ice-cold (4 °C) physiological salt solution (PSS). The 
PSS solution had the following composition (in mM): NaCl 120.0, NaHC03 20.0, KC1 4.1, 
KH2P04 1.2, MgCl2 1.2, CaCl2 1.5 and glucose 11.0; pH: 7.4. The penile artery was carefully 
dissected and cleaned from the adherent connective tissue. Ring segments (ca. 2 mm long) 
were mounted on two 40 pm wires of isometric double myograph (Danish Myotechnology, 
Aarhus, Denmark) according to Mulvany as described in 3.1.1. The preparations were 
allowed to equilibrate in PSS solution at 37 C and pH 7.4, for 30 minutes.
3.3.2. Experimental protocol for the measurement of isometric tension
To test the contractility of the preparations, they were exposed twice to phenylephrine 
(PE, 10 pM). The presence of intact endothelium was evaluated by inducing a stable 
contraction with phenylephrine (10 pM) followed by addition of Ach (10 pM). Relaxation 
greater than 50% was taken as evidence of endothelial integrity. Arteries were incubated with 
LNA (100 pM) and indomethacin (10 pM) for 20 minutes before being contracted with 
Phenylephrine (3 pM), and cumulative concentration-response curves were constructed for 
CNP (0.01-1 pM). When the effects of inhibition of K+ channels were tested, the arteries
were incubated for 20 minutes with either the combination of charybdotoxin (0.1 pM) plus 
apamin (0.5 pM), charybdotoxin (0.1 pM), or iberiotoxin (0.1 pM).
3.3.3. Experimental protocol for the measurement of membrane potential
Membrane potential measurements were conducted according to 3.2.3. Drugs (CNP 
(1.4 pM), Ach (10 pM)) were added directly to the organ bath.
3.4. Drugs
The components of the KH solution and barium-chloride were obtained from Reanal 
(Budapest, Hungary). The prostaglandin analogue, U46619 (9,11-dideoxy-l l a,9a,-
ePoxymethano-prostaglandin F2a), acetylcholine chloride, bradykinin-acetate, L-co-nitro 
arginine, indomethacin, phosphoramidon [N-(a-Rhamnopyranosylphosphono)-L-leucyl-L- 
Iriptophan disodium salt], thiorphan [(DL-3-mercapto-2-benzylpropanoyl)-glycine], 
PD 142893 (N-Acetyl-P-Phenyl-D-Phe-Leu-Asp-Ile-Ile-Trp), natriuretic peptide, C-type (Gly-
Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-
Cys), cromakalim, charybdotoxin, apamin, iberiotoxin and ouabain were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Calcium ionophore A23187 (Calcimycin; C29H37N3O6) 
was purchased from Fluka Chemie AG (Buchs, Switzerland). The source of levosimendan 
and OR-2828 was the ORION PHARMA (Espoo, Finland).
U46619 was dissolved in 96 % ethanol in order to obtain a stock solution of 0.4 mM. 
Acetylcholine chloride, charybdotoxin and apamin were dissolved in double-distilled water to 
8lve 1 mM, 23 pM and 50 pM stock solutions, respectively. Bradykinin was dissolved in 
distilled water, phosphoramidon, thiorphan, PD 142893 and U46619 were dissolved in 96% 
ethanol. A23187 was dissolved in 1% dimethyl sulfoxide. Cromakalim was dissolved in 
distilled water containing 70% ethanol.
All stock solutions were stored frozen at -20 °C. The appropriate dilutions were 
obtained by freshly diluting the stocks with KH solution.
3.5. Data analysis & data handling
3.5.1. Data analysis of isometric force studies
Degree of the induced vasoconstriction was expressed in millinewton (mN). Any 
further change of the vascular tone resulted by the application of the observed substances was 
calculated as percent of the induced steady-state contraction amplitude of the same 
preparation. Data are shown as mean ± standard error of the mean (s.e.m.). The effective 
concentration, which caused 50% of maximum relaxation, was defined as EC50. For the 
calculation of EC50 values the (a*x)/(x+b) logistic equation was fitted to the individual 
concentration-response curves, in some experiments to the individual curves, in order to 
calculate differences between them. Statistical significance was tested with Student’s two 
tailed paired t-test and with one-way analysis of variance (ANOVA). Values of P less than 
0.05 were considered statistically significant. Correlation between hyperpolarizing and 
vasodilatator effect was calculated by the linear regressional analysis of the paired data.
3.5.2. Data analysis of membrane potential measurements
In each experiment the stable membrane potential value measured after the successful 
impalement was considered as baseline. The hyperpolarizing effect was calculated as a 
difference between the baseline value and the measured most negative potential after adding 
the substance. Data are shown as mean ± s.e.m. for n observations, where n equals the number 
of cells from different coronary arteries in which membrane potential was recorded. Statistical 
analysis was performed by one-way ANOVA and the non-parametric Wilcoxon-test. Values 
of P less than 0.05 were considered statistically significant.
3.5.3. Data handling
Calculations were performed by the assistance of the following programs: Microsoft® 
Excel 2002, GraphPad® Prism 3.0, Nfit® 1.0, Cole-Parmer® Companion 3.61.
3.6. Ethics
All animals received human care, the procedure of handling all the animals, their care met the 
requirements of Guide for the Care and Use of Laboratory Animals and the experimental 
Protocols were approved by the Ethical Review Board for Animal Experiments of the
University of Szeged, Hungary (I 74-3/2002.MÁB.sz). The procedures with human penile 
tissues were in accordance with the permission granted by the Ethical Committee of the 
University of Szeged (No.l988/Szeged Tudományegyetem [SZTE]).
4. RESULTS
4.1. Conductance arteries
4.1.1. Vasorelaxant effect of CNP on rat isolated arteries
Vasorelaxant effect of CNP was examined on three different types of rat isolated 
conductance type arteries in vitro. CNP exerted dose dependent relaxations in rat femoral, 
carotid and superior mesenteric arteries. (Fig. 3.). CNP relaxed the phenylephrine contracted 
carotid and mesenteric arteries to a larger extent than the femoral arteries. The measured 
maximal vasorelaxant effects of the peptide were the following: artéria carotis: 86.4±2.9% 
(n=5); artéria mesenterica superior: 72.6±4.1% (n=9); artéria femoralis: 22.1±4.6% (n=7). 
The calculated EC50 values were in the same magnitude: artéria carotis: 7.9 * 10'7 M; artéria 
mesenterica superior: 7.0 * 10'7 M; artéria femoralis: 1.8 * 10'7 M. Using the equation of y= 
a*x/(x+b), 1 pM CNP can cause 81.0% relaxation in the carotid artery, 74.5% in mesenteric 
artery and 31.0% in femoral artery. These calculated values are close to the measured 
maximal values, as described above. Consequently, 1 pM concentration of CNP is able to 
exert submaximal relaxations of the systemic blood vessels studied.
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Figure 3.
Vasorelaxant effect of C-type natriuretic peptide (CNP) in three different types of arteries 
isolated from rat
The meanis.e.m. values represent the maximal vasodilating effects of 1 pM CNP. Results are 
expressed as percentage of the contractions induced by phenylephrine. ’pO.05 show 
significant differences in CNP induced relaxations compared to arteria femoralis and, #p<0.05 
to arteria mesenterica superior.
Based on these results we tested the vasodilator capacity of the substance on a 
specialized and highlighted type of vessels: coronary arteries.
4-1.2. Effect of CNP on porcine isolated coronary arteries
4-1 -2.1 .Characterization of the endothelial function in porcine coronary artery
Fig. 4. shows the effect of endothelial stimulants, bradykinin and A23187, on the tone 
°f coronary ring preparations precontracted with the prostaglandin analogue, U46619 
Experiments were conducted in isolated arteries in the presence (■) and absence (□) of 
endothelium (n=8 and 9, respectively). When bradykinin was used as the endothelial 
stimulant, the steady-state tone induced by U46619 was comparable in the presence and 
absence of endothelium (84.5±7.2 mN, n=8 and 87.6±16.3 mN, n=9, respectively). 1 pM
bradykinin caused relaxation in endothelium intact coronary arteries while it contracted the 
endothelium denuded preparations. In experiments with the calcium ionophore, A23187, the 
contractions induced by U46619 were similar in the two groups (with endothelium: 80.8±6.9 
mN, n=8 and without endothelium: 84.5*11.4 mN, n-9). 0.5 gM A23187 caused relaxations 
of endothelium intact coronary arteries and, in contrast to bradykinin, did not affect the tone 
of endothelium-deprived U46619 precontracted coronary arteries.
Figure 4.
Effect of bradykinin (1 (iM) and the calcium ionophore, A23187 (0.5 pM), on the tone of 
porcine isolated coronary arteries. Endothelium intact (■) and endothelium deprived (□) 
arterial rings were investigated (n=8 and 9, respectively). Dataware shown as percent changes 
in tension induced by U46619 and presented as means ±s.e.m. p<0.001
Since endothelial function is vulnerable and determined by many independent factors, 
in order to retrieve comparable data, we tested the endothelial function by bradykinin (1 pM) 
before each measurment to evaluate the presence and absence of functional endothelium.
4.1.2.2. Vasorelaxant effect of CNP on porcine coronary arteries
4.1.2.2.1. Effect of phosphoramidon on the C-type natriuretic peptide-induced relaxation 
Another series of experiments were aimed at determining the capacity of phosphoramidon to 
modify the CNP induced relaxations in porcine coronary arteries (Fig. 5).
Figure 5.
Effect of phosphoramidon (10 pM) on the relaxations induced by C-type natriuretic peptide 
(CNP) in porcine isolated coronary arteries.
Experiments were performed in the presence (A) and absence (B) of endothelium (n=8 and 8, 
respectively). Data are shown as percent changes in tension induced by U46619 and presented 
as means ± s.e.m. Statistical significance in the magnitude of CNP exerted relaxations is 
marked (*) between phosphoramidon pretreated (*,o) and solvent control (■,□) groups. 
*p<0.05
In the presence of functional endothelium CNP exerted concentration-dependent 
relaxations with a maximum of 36.4±4.5% at 1.4 pM of the peptide against U46619-induced 
contractions (Fig. 5 A). 10 pM phosphoramidon significantly enhanced the effect of CNP at 
as low as 0.018 pM concentration of the natriuretic peptide and increased the maximal effect 
of CNP (from 36.4±4.5% to 56.2±6.2%, n=8, p<0.05). The calculated EC5o value of CNP was 
0.042±0.008 pM and this value was not changed significantly by phosphoramidon
(0.031±0.012pM).
Fig. 5 B depicts that, in the absence of functional endothelium, the relaxing capacity of 
CNP virtually did not differ from that obtained with endothelium intact coronary artery 
preparations. The relaxing efficacy of CNP was 38.3±4.8% (n=8). Phosphoramidon increased 
the magnitude of this relaxation to 55.4±5.1% (n=8) and decreased, albeit not significantly, 
the EC50 of the natriuretic peptide (EC5o CNP: 0.056±0.06 pM vs EC50 
CNP+phosphoramidon: 0.033±0.09 pM).
4.1.2.2.2. Effect of thiorphan on the C-type natriuretic peptide-induced relaxation
This series of experiments was devoted to study the effect of thiorphan on the 
coronary artery relaxations induced by CNP (Fig. 6). In the endothelium intact preparations 
0.006-1 4 pM CNP alone exerted similar relaxations to those obtained in the previous series 
of experiments (Fig. 5). 10 pM thiorphan enhanced the relaxations induced by CNP which 
was found to be significant at 0.036 pM concentration of the natriuretic peptide (Fig. 6. A). 
The EC50 value of CNP was 0.053±0.010 pM without thiorphan (n=8) and 0.035±0.011 pM 
with thiorphan (n=8).
Fig. 6. B shows the effect of thiorphan on the endothelium independent relaxations to 
CNP. At the maximum concentration of CNP, that is 1.4 pM, the average relaxation was 
33.0±4.7 % (n=8) which was smaller, although not significantly, than that obtained in the 
presence of endothelium (41.4±5.1%, n=8). Similar to the endothelium intact coronary 
arteries, the endothelium independent relaxation by CNP was enhanced by tiorphan (to 
47.1±5.4%, n=8). Thiorphan did not change the EC50 of the natriuretic peptide (EC50 CNP: 
0.023±0.05 pM vs EC50 CNP+thiorphan: 0.031±0.08 pM, not significant).
Figure 6.
Effect of thiorphan (10 pM) on the relaxations induced by C-type natriuretic peptide (CNP) in 
porcine isolated coronary arteries. Experiments were performed in the presence (A) and 
absence (B) of endothelium (n=8 and 8, respectively). Data are shown as percent changes in 
tension induced by U46619 and presented as means ± s.e.m. Statistical significance in the 
magnitude of CNP exerted relaxations is marked (*) between thiorphan pretreated (*,o) and 
solvent control (■,□) groups. p<0.05
4.1 2 3 Effect of endothelin receptor inhibition on phosphoramidon-induced potentiation of 
coronary artery relaxation
In order to explore the possible role of endothelin under our experimental conditions 
the effect of the endothelin receptor antagonist, PD142893, on CNP-induced relaxation was 
also investigated. Incubation of the coronary artery rings with 10 pM endothelin antagonist 
did not change the U46619-induced contraction with and without endothelium (74.6±6.4 mN, 
n=9 ^  83.1±9.9mN, n=8, respectively). As shown in Table 2. PD142893 alone caused a 
small, insignificant increase in the basal tone compared to its solvent suggesting the lack of 
basal endothelin release in this artery. It is conceivable, however, that the vasorelaxing effect 
of low concentration of CNP was potentiated by the inhibition of endothelin receptors in the 
presence but not in the absence of endothelium.
Table 2. Effect of the endothelin receptor blocker, PD142893, on the C-type natiuretic peptide 
(CNP)-induced relaxation in porcine coronary artery
Relaxation in percent of U46619-induced tone
agent with endothelium without endothelium
solvent 
of PD142893 1.3±0.8 % 0.7±1.1 %
solvent + CNP 
(0.02 pM) 5.4±3.6 % 13.1±4.1 %
PD 142893 (10 pM) 3.5±1.6 % 2.7±4.4 %
PD 142893 (10 pM) 
+ CNP (0.02 pM) 16.7±4.0%*i 10.3±5.2 %
Values are means ± s.e.m., n=8-9 per group. *p<0.05 statistical significance vs. solvent+CNP 
with endothelium; :p<0.01 statistical significance vs. PD 142893 with endothelium
4.1.2.4. Hyperpolarizing effect of CNP in porcine coronary arteries
CNP is considered as a candidate for endothelium-derived hyperpolarizing factor 
(EDHF) [22 34] resulting in hyperpolarization and consequent relaxation of the vascular 
smooth muscle cells. In order to prove the hyperpolarizing capacity of the substance we 
performed electrophysiological measurements on porcine isolated coronary arteries. Resting 
membrane potential of smooth muscle cells was established before each mesasurement and 
was considered as baseline. Before the appication of CNP in 1.4 pM concentration baseline of 
the resting-tone membrane potentials of the smooth muscle cells was -49.79±1.4 mV (n=15), 
that was reduced to -53.12±1.2 mV, n=15 (Fig. 7.). This significant decrease apparently prove 
the hyperpolarizing ability of this endogenous peptide on isolated porcine coronary arteries.
CNP achieved detectable, but insignificant hyperpolarization in 0.7 and 2.1 pM 
concentration.
CNP 0.7 CNP 1.4 CNP 2.1
baseline(A) pmol/1 baseline(B) pmol/1 baseline(C) pmol/1
Figure 7.
Hyperpolarizing effect of C-type natriuretic peptide (CNP) on porcine coronary arterial 
smooth muscle cells
Membrane potentials are shown as mean±s.e.m. values before (baseline (A-C)) and after 
administration of CNP (0.7-2.1 pM). *p<0.05 show significant difference compared to 
baseline(B) in CNP induced hyperpolarization.
4.1.2.5. Comparison of relaxation and hyperpolarization elicited by different doses of CNP
Relaxation and hyperpolarization as responses to concentrations of CNP were plotted 
in the same coordinate system, to reveal if any correspondence is present between their dose- 
dependence. (Fig. 8.). The dose-response curve of hyperpolarization covers a well defined 
segment of the relaxation curve, showing that hyperpolarization can be a considerable 
component of CNP induced relaxation, at least, in the large concentrations of the peptide.
CNP concentration (pM)
— • —  Relaxation
■  Hyperpolarization
Figure 8.
Concentration dependence of C-type natriuretic peptide (CNP) induced relaxation and 
hyperpolarization
Arbitrary units (0-100) were applied in order to obtain comparable data. The maximal 
hyperpolarization obtained from Fig. 7. and maximal relaxation from Fig. 5.A. were 
considered as 100 arbitrary units.
4.1.3. Correlation between CNP induced relaxation and hyperpolarization
In order to prove the connection between CNP induced relaxation and 
hyperpolarization a simultaneous measurement of the two parameters has been recorded (Fig. 
9.). The mounted rat mesenteric artery was precontracted by noradrenaline (NA) and, after the 
insertion of the intracellular microelectrode, effects of three doses of CNP (166 nM, 500 nM,
1.6 pM) and a single dose of Ach (10 pM) were investigated. In this experiment 500 nM and
1.6 pM CNP decreased the vacular tone of the NA precontracted vessels. 1.6 pM CNP 
produced a hyperpolarizing effect on the impaled smooth muele cell (-3.7 mV). Lower doses 
of CNP did not influence the development of NA induced depolarization. These data are in 
agreement with our previous calculations on porcine coronary arteries. Application of Ach 
(10 pM) resulted in further decrease of the vascular tone and caused a fast and marked
hyperpolarization (-12.7 mV). Dislocation of the electrode prevented us from the continuance 
of the experiment that is visible as an irregular shake of the membrane potential record.
Figure 9.
Original recording of vascular tone and membrane potential in a simultaneous measurement 
The two charts are representing the changes of membrane potential (upper) and vascular 
changes (lower). Units of tone (mN) and membrane potential changes (mV) as well as the 
time scale (min) are shown. After the development of NA (5 pM) induced contraction a 
smooth muscle cell was impaled resulting in a sudden drop of the membrane potential. 
Hyperpolarization induced by 1.6 pM CNP preceeds the relaxation in time. 500 nM CNP 
caused relaxation without a preliminary hyperpolarizing effect of the peptide.
C-type natriuretic peptide as an EDHF-like endogenous vasodilator can be applied as a 
reference substance in the development of new vasodilator molecules. In the next series of our 
experiments we compared the vasoactive capacity of CNP with levosimendan and OR-2828.
4.1.4. Investigation of the possible inodilator capacity of OR-2828
4.1.4.1. Effect of OR-2828 on isometric tone of porcine coronary artery
OR-2828 elicited concentration-dependent relaxation (0.38 pM -  230.6 pM) in the 
porcine isolated coronary artery. Fig. 10. shows the magnitude of this relaxation in the 
percentage of the applied KC1 (30 mM) precontraction. As the solvent for OR-2828 itself 
evoked relexation, its effect was deducted from that obtained with the corresponding 
concentrations of OR-2828 and the curve represents the net effect of the compound. The
calculated maximum relaxation (a) of OR-2828 was 78.1 % and the ECS0 value (b) was found 
to be 72.2 pM.
Fig. 10.
Effect of OR-2828 on precontracted porcine coronary artery
The vasodilating effects of OR-2828 are shown as percentage of KC1 (30 mM) induced 
contractions. Data are shown as mean±s.e.m. values. The application of the substance resulted 
in a dose-dependent relaxation of the coronary artery.
4.1.4.2. Effect of OR-2828 in comparison to C-type natriuretic peptide and levosimendan on
membrane potential of the coronary artery smooth muscle
Fig. 11. (representative record) and Fig. 12. demonstrate the hyperpolarizing effect 
evoked by CNP and the two coronary artery dilators (OR-2828 and levosimendan) on isolated 
porcine coronary arterial smooth muscle cells.
Fig. 11. shows the magnitude of hyperpolarization induced by the three compounds. The basal 
membrane potential values are obtained from three different experiments. The 
hyperpolarizing effect of the reference substance, CNP (1.4 pM), was -3,7 mV. OR-2828
concentration-dependently decreased the membrane potential with a maximum of -2.8 mV at
120 pM. Levosimendan (3,7 pM) caused -2.2 mV hyperpolarization at 3.7 pM.
Levosimendan
Figure 11.
Representative chart showing changes of membrane potential induced by C-type natriuretic 
peptide (CNP), OR-2828 and levosimendan
Temporal membrane potential changes represent hyperpolarizations after application of CNP 
(1.4 pM), OR-2828 (60-180 pM) and levosimendan (3.7 pM). The breaks in the chart show
separate impalements.
Fig. 12. demonstrates the mean changes in membrane potentials obtained from 10-22 
independent electrode impalements. Before addition of CNP the resting membrane potential 
of coronary smooth muscle cells were -49.9±0.92 mV (n=17). 1.4 pM CNP caused an average 
of -3.6±0.38 mV hyperpolarization. Resting membrane potentials were determined before 
each concentration of OR-2828 (60, 120 and 180 pM). These membrane potentials were: - 
48.8±1.15 mV (n=14); -48.8±0.88 mV (n=10) and -50.3±0.41 mV (n=12). The magnitude of 
changes in hyperpolarization induced by 60, 120 and 180 pM OR-2828 were found to be - 
1.8±0.35 mV, -2.6±0.81 mV and -2.3±0.99 mV, respectively. The hyperpolarizing effect of 
60 pM OR-2828 was calculated to be significantly less than that obtained with 1.4 pM CNP. 
Resting membrane potentials before 1.8, 3.7 and 5.5 pM levosimendan were -49.7±0.79 mV 
(n=18)- -50.8±0.96 mV (n=22) and -50.9±1.18 mV (n=15), respectively. Maximum 
hyperpolarization by this inodilator was obtained at 3.7 pM (-1.82±0.44 mV). All the 
concentrations of levosimendan produced significantly less hyperpolarizations than that 
obtained with the reference compound, CNP.
Figure 12.
Changes of membrane potential induced by C-type natriuretic peptide (CNP), OR-2828 and 
levosimendan
CNP (1.4 pM), OR-2828 (60-180 pM) and levosimendan (1.8-5.5 pM) induced membrane 
potential changes are shown as mean±s.e.m. values. The data were retrieved from different 
preparations (n= 10-22). All the applied substances hyperpolarized the smooth muscle cells. 
The magnitude of hyperpolarization was compared to the effect of CNP; statistical 
significance is shown. p<0.05.
4.1.4.3. Correlation between hyperpolarization and relaxation induced by OR-2828
Fig 13. demonstrates that the magnitude of OR-2828-induced hyperpolarization, 
expressed as mV values of changes in membrane potential, showed correlation with 
relaxation. Individual values of both hyperpolarization and relaxation represent experiments 
with 60 pM OR-2828. As the effect of this concentration fits to the slope of the concentration- 
response curve of the compound (see Fig. 10.), linear correlation of the individual relaxing 
values with hyperpolarization was carried out. Equation of the correlation was y=13.4*x+18.7
(r=0.75, p<0.01).
The slope value (13.4) divided by 3.2 shows that 1 mV hyperpolarization is 
responsible for 4.2 % relaxation. The y intercept reveals that this calculation is valid only 
above 18.7 % relaxation by OR-2828.
Figure 13. . , ,  , . .
Correlation between OR-2828 induced relaxation and hyperpolanzation 
Effect o f 60 pM OR-2828 on hyperpolarization (y axis) and relaxation (x axis) are shown. 
The values o f OR-2828 exerted hyperpolarization (y axis) and relaxation (x axise) are shown. 
Linear regression analysis revealed an acceptable correlation between hyperpolarization and 
relaxation (r=0.75), the best fitting line is drawn with two lines of the standard error (dotted
lines).
4.1.4.4. Comparison of relaxation and hyperpolarization elicited by differrent doses of OR- 
2828
The concentration dependence of OR-2828 induced vasodilation and hyperpolarization 
was plotted in the same coordinate system. (Fig. 14.). The curve of relaxation overlaps with 
the curve of hyperpolarization at the investigated doses. The synthetized substance, OR-2828 
is able to hyperpolarize the smooth muscle cell membrane in a wider range of concentrations 
compared to CNP (Fig. 8). Lack of data does not allow us to state that OR-2828 is able to 
achieve any hyperpolarization at concentrations lower than 60 pM, but it is important to note 
that, facing to CNP, the synthetic substance is able to decrease the value of resting membrane 
potential at concentration lower than the ECso value of relaxation (72.2 pM).
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Concentration dependence of OR-2828 induced relaxation and hyperpolarization 
Arbitrary units (0-100) were applied in order to obtain comparable data. The maximal 
hyperpolarization obtained from Fig. 7. (2.6 mV) and maximal relaxation (see Fig. 10.: 
57.2%) were considered as 100 arbitrary units.
4.1.4 5 Effect of the voltage dependent potassium channel inhibitor, 4-aminopyridine on OR- 
2828-induced relaxation
Pretreatment of the coronary preparations with 5 mM 4-AP for 10 min resulted in a 
moderate but not significant enhancement of the KCl-induced tone (control: 48.6±9.83 mN; 
4-AP- 73 4±10.29 mN, n=5). 4-aminopyridine (5 mM) decreased the coronary artery 
relaxation induced by 41.6 and 117.2 pM OR-2828. Mean relaxing values of OR-2828 in this 
figure were obtained after deducting the effect of the corresponding volumes of the solvent. 4- 
AP had no effect on the relaxations induced by the solvent of OR-2828 (n=5). The blocker of 
the Kv channels significantly decreased the OR-2828-induced relaxation from 44.0±8.52% to 
30.3±5 17% at 41.6 pM (p<0.05, n=5). At 117.2 pM concentration of OR-2828 the relaxation 
was also significantly reduced by 4-AP from 65.6±1.34% to 52.3±3.15% (p<0.05, n=5). At 
the largest concentration of OR-2828 4-AP did not influence the relaxation.
Figure 15.
Effect of 4-AP pretreatment on the vasorelaxant effect of OR-2828
Vasorelaxant effects of OR-2828 (41.6-230.6 pM ) are shown (□) as mean ± s.e.m. values in 
the percentage of KC1 induced contractions. 4-AP significantly ( p<0.05) decreased the effect 
of OR-2828 (■) at concentcentrations of 41.6 pM and 117.2 pM.
4.2. Resistance type vessel - human penile artery
4.2.1. Vasorelaxant effect of CNP on human penile arteries
In arteries with endothelium and contracted with phenylephrine in the presence of NG- 
nitro-L-arginine (LNA) and indomethacin, CNP (0.01-1 mM) evoked concentration- 
dependent relaxations (Figure 16.). The concentration-response curves for CNP were 
reproducible up to three times (n=4) and were unaltered in preparations without endothelium 
(n=2, results not shown).
A V 1W. .
Average relaxations evoked by C-type natriuretic peptide (CNP) in human penile small
Series. . , . ,
The mean of five experiments obtained from four patients are shown in the presence of NG-
nitro-L-arginine (10'4 M) and indomethacin (10'5 M). CNP resulted in dose dependent 
relaxation of the arteries. Data are shown as percent changes in tension induced by 
phenylephrine (PE) and presented as means ± s.e.m. The measured maximal relaxation was 
68±11% at 1 pM concentration of the peptide.
4.2.2. Hyperpolarizing effect of CNP on human isolated penile arteries
Smooth muscle membrane potential in resting, untreated arterial preparations was 
-44.8±1 3 mV (n=12). In endothelium intact preparations, infusion of Ach (10 pM) 
hyperpolarized membrane potential by -5.2±0.9 mV (n=6), while infusion of an equieffective 
relaxant concentration of CNP (1.4 pM) hyperpolarized smooth muscle membrane potential 
by -2 5±0 5 mV (n= 10; Figure 18.A, B). Mechanical removal of the endothelium abolished 
the Ach-evoked hyperpolarization (0.2±0.3 mV, n= 7), while the CNP evoked 
hyperpolarization was unchanged (2.4±0.6 mV, n=10; Figure 18.C.D).
Figue 17.
Acetylcholine (ACh) and C-type natriuretic peptide (CNP) hyperpolarizes human penile 
arteries. Original recordings (panels A, C) and averages (panels B, D) of smooth muscle cell 
membrane potential changes (AEm) induced by Ach (10 pM) and CNP (1.4 pM) in penile 
arterial segments with endothelium (A, B) and without endothelium (B, D). Significant 
differences were evaluated by paired t-test. *p< 0.05 vs. arterial segment without endothelium.
4.2.3. Investigation of the involvement of BKca channels in CNP-evoked relaxation
To test whether BKca channels were involved in CNP-evoked relaxation, the blood 
vessels were incubated with iberiotoxin (0.1 pM).
Figure 18.
Original traces showing the relaxing effect of increasing concentrations of CNP in 
phenylehprine (PE) precontracted human penile small arteries in the absence and presence of 
a blocker of BKca channels, iberiotoxin (A and B respectively). The horizontal lines indicate 
time, and the vertical lines indicate increase in force (mN). The experiments were performed 
in the presence of an inhibitor of nitric oxide synthase, NG-nitro-L-arginine (L-NOARG, 100 
pM), and an inhibitor of cyclooxygenase, indomethacin (INDO, 10 pM).
Application of C-type natriuretic peptide in cumulative manner resulted in dose 
dependent relaxation of phenylephrine-precontracted penile small arteries. As it is visible in 
the presence of iberiotoxin the concentration-response curves for CNP was markedly reduced 
(Figure 18.B) compared to parallel control experiment (Figure 18.A).
This result unequivocally shows that large-conductance Ca2+-activated K (BKCa) channels are 
involved in C-type natriuretic peptide (CNP)-evoked relaxation.
5. DISCUSSION
5.1. Conductance arteries
In the first part of our experiments we have demonstrated the vasorelaxant potency of 
CNP on rat isolated femoral, mesenterial and carotid arteries. CNP had unequivocal 
vasorelaxant effect on all the tree types of arteries, nevertheless the most outstanding impact 
was observed in carotid arteries.
In the second series of our experiments we have demonstrated the functional 
importance of the inhibition of neutral endopeptidase 24.11. activity in the augmentation of 
the coronary artery relaxation induced by C-type natriuretic peptide. Two known inhibitors of 
NEP, phosphoramidon and thiorphan, potentiated the effect of CNP both in the presence and 
absence of functional endothelium. Our results are in agreement with those obtained in other
animal species in vivo that CNP is a vasodilating mediator and NEP is an important 
elimination pathway of this type of natriuretic peptides in the coronary circulation [35,36].
We have characterized the reactivity of porcine coronary artery to bradykinin and the 
A23187 calcium-ionophore in the presence and abscence of functional endothelium. 
Bradykinin and A23187 caused relaxation in porcine coronary artery preparations with intact 
endothelium. Following the mechanical removal of the endothelium bradykinin caused 
contraction of the coronary artery preparations. The efficiency of endothelial damage was 
proved by the disappearance of calcium ionophore induced vasodilation, representing the lack 
of all calcium-mediated, receptorial independent functions of the endothelial cells, such as the 
production of nitric oxide and endothelium-derived hyperpolarizing factor.
CNP relaxed both intact and deendothelized porcine isolated coronary artery rings 
showing endothelium-independent vasodilator potency. Therefore in contrast to bradykinin, 
CNP does not require the mediation of nitric oxide or prostaglandins for producing 
vasorelaxation [37]. In the present experiments CNP relaxed the porcine coronary artery, an 
effect which was almost the same in magnitudes and similar in potency values both in 
endothelium intact and endothelium deprived preparations. These results match the findings 
obtained by others in the same blood vessel [38]. Our experimental conditions simulate a 
selective damage of the endothelial ’vasodilator reserve’ in that CNP is superior to bradykinin 
for preventing local vasoconstriction. The relevance of this superiority to in vivo conditions is 
supported by the presence of CNP in those parts of large coronary arteries known to have 
dysfunctional endothelium, i.e. the atherosclerotic plaque. Moreover, the CNP gene has been 
found, besides the endothelium, in smooth muscle cells of the human coronary arteries 
including samples of early and advanced atherosclerotic lesions [39]. The adenovirus 
mediated gene transfer to the damaged area of large coronary arteries has been demonstrated 
to prevent coronary restenosis after balloon injury in pigs [40].
Inhibitors of neutral endopeptidase enzyme (EC. 3.4.24.11.), phosphoramidon and 
thiorphan, potentiated the vasorelaxing effect of CNP both on intact and endothelium 
deprived coronary arteries. NEP is the primary enzymatic elimination pathway for CNP 
limiting the available concentration of the peptide in the vascular wall. The enzyme is known 
to be located on the surface of the endothelial cells and as an ectoenzyme degrades and 
inactivates several other vasoactive peptides in the blood circulation [16,41,42]. Recent
studies have demonstrated that the enzyme is constitutively expressed in the rat and human 
vascular smooth muscle cells [43-45]. Phosphoramidon was able to potentiate the effect of 
bradykinin in the presence of damaged endothelial function of the porcine coronary artery
[46].
In the presence of endothelium the production of endothelin, known to be a strong 
vasoconstrictor mediator, may counteract the vasorelaxing effect of CNP. In a series of our 
experiments, in which thiorphan was used to modulate the effect of CNP, 0.018 pM peptide 
alone caused a virtually smaller relaxation in the presence of endothelium compared to those 
obtained in the endothelium deprived preparations (see Fig. 5.). In the presence of 0.018 pM 
CNP, phosphoramidon, known to exhibit an inhibitory effect on endothelin converting 
enzyme, resulted in a significant increase of the vasorelaxation in endothelium intact coronary 
artery. This effect was not observed in the endothelium denuded preparations (see Fig. 4.). 
Inhibition of the endothelin receptors by PD 142893 increased the 0.02 pM CNP-induced 
coronary artery relaxation to similar extent as obtained with phosphoramidon. The effect was 
found only in the presence of endothelium. These results together are indicative of a 
functional antagonism between CNP and endothelin in this artery and demonstrate the 
sensitivity of the porcine large coronary arteries to endothelin converting enzyme inhibition as
was also showed in some human studies [47,48].
Recent studies have supported that hyperpolarization is an efficient vasodilating 
mechanism regulating the tension of the conduit type of coronary arteries [49]. In addition to 
nitric oxide and vasodilator prostaglandins, the EDHF is an endogenous mediator released 
from the vascular endothelium. Although nitric oxide by itself is able to hyperpolarize the 
smooth muscle membrane, a nitric oxide independent EDHF has also been demonstrated in 
the regulation of porcine, canine and human coronary artery tone [49-52]. An independent 
EDHF was shown to play roles in relaxation of coronary arteries in experimental heart failure 
and coronary angioplasty, under pathological conditions in which nitric oxide production was 
impaired [53-55]. These findings serve the basis for developing hyperpolarizing coronary
artery vasodilators.
The results of membrane potential measurements on porcine coronary artery smooth 
muscle cells indicate that the hyperpolarization of the smooth muscle membrane plays an 
important role in the regulation of coronary arterial tone. CNP was able to decrease the resting
membrane potential of the smooth muscle cells isolated from porcine coronary arteries. The 
measured hyperpolarization was in accordance with the results of Barton et al. [38], who 
demonstrated -4.4 mV maximal change in the resing membrane potential in similar
conditions.
The hyperpolarizing effect of CNP was pronounced at micromolar concentrations of 
the peptide, where the maximal vasorelaxation was previously measured. This fact denotes 
that CNP induced hyperpolarization is an important component of the vasorelaxation. 
Although different simultanous mechanisms are supposed to generate the complex effect of 
the peptide (NPR-B, NPR-C, K+ channels), in physiologic conditions CNP induced 
hyperpolarization seems to be an accessory, subsidiary factor in the development of its 
vasorelaxant effect, as CNP is proved to be efficient vasorelaxant factor even in those lower 
concentrations, where membrane potential change was not detected. According to recent 
findings hyperpolarization comes to prominence as a major vasorelaxant factor when 
vasorelaxant capacity is decreased due to pathologic changes. This is indicative of the 
importance of such a mechanism as a possible therapeutic pathway in the augmentation of 
endogenous vasorelaxation. The limitation of the method necessitates further investigation of 
the observed phenomenon.
In the next series of our experiments we have demonstrated the coronary artery 
dilating and hyperpolarizing effects of OR-2828 and levosimendan in comparison to C-type 
natriuretic peptide, as a reference substance. Maximum increase of the resting membrane 
potential induced by OR-2828 was similar to that obtained with CNP, while the effect of 
levosimendan was found to be smaller than that produced by the known peptidergic
vasomotor regulator.
OR-2828 produced less potency and efficacy values in dilating porcine coronary artery 
than that presented previously with levosimendan in the same type of coronary arteries [56]. 
The maximum hyperpolarizing effect of OR-2828, however, appears to be larger than that 
measured with levosimendan. The effect of both synthetic inodilators was compared to CNP 
because this natriuretic peptide has recently been shown to act as EDHF in rat mesenteric 
artery [21]. It was also demonstrated that CNP is one of the potential endogenous 
hyperpolarizing mediators in epicardial coronary artery of the pig [23, 38]. In this artery the 
maximum response to CNP was found to be already -3.3 mV at 1.4 pM of the peptide [57].
Therefore, we used only this concentration of CNP as reference for comparing the magnitude 
of hyperpolarization induced by OR-2828 or levosimendan.
While hyperpolarization is the main vasodilating mechanism in resistance arteries, 
conduit arteries, like epicardial large coronary vessels, do not belong to the category of 
’EDHF-type’ arteries [58]. This is an explanation why the magnitude of changes in membrane 
potential was relatively small in the present study and the finding is in agreement with those 
measured by other authors. Our values of CNP-induced hyperpolarization (-3.6 mV on 
average) are comparable to those obtained with the peptide (~ -4-5 mV) or with an ATP- 
sensitive potassium channel opener, levcromakalim (~ -4 mV), in other experiments [38,59].
We presented the first evidence that at the maximal vasorelaxing concentrations of 
levosimendan (~ 1-3 pM) [56], the inodilator hyperpolarizes the coronary artery. The 
hyperpolarizing sensitivity of levosimendan is similar to that obtained in a resistance type of 
arteries (levosimendan EC50=2.9 pM) [60]. It is important to note that the magnitude of 
hyperpolarization is much less in our epicardial coronary artery preparations than that 
produced maximally in a resistance type artery, such as the rat mesenteric artery [21, 60].
However, some mV changes in the membrane potential might considerably influence 
vascular tone. In our present observations correlation between the hyperpolarizing and 
relaxing effects of OR-2828 showed that 1 mV increase of membrane potential is coupled 
with 4.2 % relaxation. This value is almost the same as found in rat mesenteric artery (4.3%/l
mV) [61].
In porcine coronary artery, voltage-dependent potassium channels regulate the tone 
both at resting and stimulated conditions [62,63], Concerning the mechanism of action, OR- 
2828 appears to activate, at least in part, the 4-aminopyridine-sensitive voltage-dependent 
potassium channels. In this respect, the drug resembles levosimendan which relaxes porcine 
coronary arteries partly through voltage-dependent as well as calcium-dependent potassium 
channels [64]. 4-aminopyridine-sensitive potassium channels were proposed to play a role in 
the coronary artery vasomotor tone under pathological conditions, as demonstrated in human 
coronary arteries [65]. Beneficial haemodynamic effects of both OR-2828 (our unpublished 
observation) and levosimendan [66] have been presented in experiments performed in 
pathological cardiac models in the dog, and with levosimendan in human severe heart failure 
[67]. In addition, more recent observations have revealed direct inhibition by high-fat diet and
cholesterol of 4-aminopyridine-sensitive potassium channels, thereby disturbing adenosine- 
mediated coronary autoregulation [68,69]. High glucose level also directly impairs 4- 
aminopyridine-sensitive voltage-dependent potassium channels [70].
5.2. Resistance arteries
Our findings provide, for the first time, evidence suggesting that CNP possesses the 
characteristics of an EDHF contributing to vasodilation of human penile small arteries (see 
Figure 16, 17). Thus, direct electrophysiological measurements revealed that CNP 
hyperpolarizes penile arterial smooth muscle. CNP caused potent relaxations which were also 
present after inhibition of NO synthase and cyclooxygenase. These EDHF type relaxations 
were inhibited in the presence of blockers of calcium-activated K+ channels, apamin plus
charybdotoxin.
As mentioned in the Introduction, several candidates may contribute to EDHF-type 
relaxation in arteries. CNP is a likely candidate for an EDHF in human penile arteries. CNP 
receptors are present in the corpus cavemosum of different species [71-73] and as we 
demonstrated in the present study, CNP evoked relaxations in the presence of inhibitors of 
NO synthase and cyclooxygenase and in arteries without endothelium. The biological activity 
of CNP can be mediated by activation of NPR-B, that is present in the corpus cavemosum of 
different species including man [71-73], and is linked to particulate guanylyl cyclase and the 
formation of cyclic guanosine monophosphate (GMP) [74], Activation of the cyclic GMP 
pathway has been found to lead to activation of both Na+/K+-ATPase and BKCa in horse 
penile arteries [75,76], and of Na/K-ATPase in human corpus cavemosum [77]. Moreover, 
CNP evoked relaxation in systemic arteries was described to be inhibited by iberiotoxin, a 
blocker of BKCa channels, [78-81]. In the present study iberiotoxin markedly reduced CNP 
relaxation suggesting BKCa channels are involved in CNP induced relaxation in human penile
small areries.
6. SUMMARY AND CONCLUSIONS
The results presented in this thesis can be summerized as follows:
1 CNP was proved to have significant relaxant effect on rat isolated systemic arteries. 
The order of maximal relaxation was found to be as follows: carotid arteries > mesenteric
arteries > femoral arteries.
2 The relaxant effect of CNP was found to be endothelium-independent in porcine 
isolated coronary arteries. The vasorelaxant effect of low concentration of CNP was 
augmented by the endothelin inhibitor, PD142893, in the presence but not in the absence of
endothelium.
3. The NEP-inhibitors (phosphramidon, thiorphan) potentiated the relaxant effect of 
CNP both in endothelium intact and endothelium deprived porcine isolated coronary artery
preparations.
4. CNP hyperpolarized the porcine isolated coronary arteries. The magnitude of OR- 
2828 exerted hyperpolarization was similar, the maximal effect of levosimendan was found to
be smaller compared to the endogenous peptide, CNP.
5. Correlation was found between hyperpolarization and relaxation induced by OR- 
2828. Kv channels partly mediated hyperpolarization as it was proved by the decrease of OR-
2828 induced relaxation by the Kv channel blocker, 4-AP.
6. The relaxant and hyperpolarizing effect of CNP was endothelium independent in 
resistance type penile arteries isolated from humans. Hyperpolarization was preserved in the 
endothelium deprived preparations, facing to the effect of the endothelium dependent 
relaxant, Ach, that was abolished.
7 CNP revealed to be a non-adrenergic/non prostaglandin type relaxing agent in 
human penile resistance arteries. BKCa channels were involved in the relaxing effect of the 
peptide as it was proved by using a selective inhibitor of the channels, iberiotoxin.
The vascular effect, the functional consequence of NEP inhibition on the blood vessel 
tone, largely depends on the kind of the peptide substrates for the enzyme available at the 
targeted area of circulation [37,82-84]. While the source of certain substrates of the enzyme, 
such as bradykinin, substance P and endothelin is the vascular endothelium, CNP has also 
been found in the medial and adventitial layers of the coronary arteries [39], Thus, local
delivery of CNP and the inhibition of its degradation may have a crucial role in the 
improvement of vasorelaxing capacity of large coronary arteries with damaged endothelium, 
e.g. atherosclerotic lesions [85]. NEP 24.11. is constitutively expressed in endothelial and 
smooth muscle cells [44,86]. The functional role of NEP in CNP degradation is proved in 
NEP/ACE inhibitor, omapatrilat, pretreated rat myocardial arterioles and capillaries by 
identification of the amplified antihypertrophic effect of the peptide compared with the effect 
of an ACE inhibitor, fosinopril [87].
The present observations raise the possibility that enhancement of hyperpolarizing and 
vasodilator effect of C-type natriuretic peptide by the inhibition of the NEP activity could 
moderate the vasospastic tendency of diseased coronary segments with endothelial 
dysfunction or with complete endothelial defect. The results suggest that NEP inhibitors could 
endue this endogenous peptide with therapeutic potency against vasospasm and strengthen the 
effect of CNP as an endogenous defensive factor against intimal hyperplasia in severe
coronary artery diseases.
The results of the comparative studies raise the possibility that coronary artery 
relaxants with hyperpolarizing effect, such as OR-2828 and levosimendan, might also be 
advantageous in some metabolic alterations leading to coronary artery diseases.
In point of the results on human penile arteries an apparent limitation of the examined 
samples could be that they were obtained from patients undergoing transsexual operations, 
and we cannot entirely exclude that hormonal treatments influence the endothelial responses. 
However, the advantage, on the other hand, is that none of the patients had cardiovascular 
disease, which is known to alter endothelium-dependent vasodilation in both systemic [88] 
and penile arteries [89-91]. Thus, in erectile tissue and penile arteries from patients with 
diabetes, endothelium dependent relaxation is blunted [92,93]. The same applies to the penile 
arteries and erectile tissue isolated from hypertensive and diabetic animals [94,95]. In penile 
arteries mainly, the EDHF-type relaxation is impaired in hypertensive animals [94]. Our data 
suggest that CNP possesses the characteristics of an EDHF in human penile resistance 
arteries, because it causes hyperpolarization of the penile smooth muscle. CNP causes potent 
relaxations sensitive to the blockers of K+ channels present both in the vascular smooth 
muscle cells and the endothelium. Modulation of this pathway opens for new treatment
modalities of erectile dysfunction.
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